Angiotensin (1-7): Mechanisms, Experimental Utility & Evidence

Executive Summary:
Angiotensin (1-7) (Ang-(1-7)) is an endogenous heptapeptide derived from angiotensin I or II by specific peptidases and exerts effects primarily via Mas receptor stimulation, counter-regulating deleterious actions of angiotensin II (Oliveira et al., 2025). Ang-(1-7) modulates PI3K/AKT and ERK signaling, influencing nitric oxide (NO), FOXO1, and COX-2, with implications across cardiovascular, renal, metabolic, and neuroprotective domains (ApexBio A1041). The peptide provides anti-fibrotic and anti-inflammatory effects in multiple organs, enhances metabolism by increasing glucose uptake and lipolysis, and reduces insulin resistance. It demonstrates distinct advantages over classical RAS agents in experimental models, with high purity and solubility for in vitro and in vivo research (Angiotensin (1-7): Applied Protocols). Reliable protocols for cell-based and animal studies are established, supporting reproducible results across diverse fields.

Biological Rationale

Angiotensin (1-7), sequence Asp-Arg-Val-Tyr-Ile-His-Pro, is a heptapeptide hormone generated from angiotensin I (1-10) or II (1-8) by endo- or carboxypeptidases (DOI). It is a key regulator within the extended renin–angiotensin system (RAS). While classical RAS actions are mediated via angiotensin II and AT1R, which promote vasoconstriction, inflammation, and fibrosis, Ang-(1-7) provides a physiological counterbalance. It acts predominantly through the Mas receptor, a G-protein-coupled receptor, to elicit vasodilation, anti-inflammatory, anti-proliferative, and anti-fibrotic responses (DOI). Activation of the Mas receptor by Ang-(1-7) is associated with enhanced nitric oxide (NO) production, improved endothelial function, and reduced oxidative stress. Ang-(1-7) is widely detected in plasma and tissues, including heart, kidney, liver, lungs, and brain. Its multi-organ distribution underpins its diverse physiological actions.

Mechanism of Action of Angiotensin (1-7)

Ang-(1-7) exerts its effects primarily by binding the Mas receptor, leading to downstream activation or inhibition of several signaling cascades. Key pathways modulated include:

• PI3K/AKT Pathway: Promotes cell survival, glucose uptake, and anti-apoptotic effects.
• ERK Signaling: Regulates cell proliferation and differentiation; Ang-(1-7) inhibits ERK phosphorylation in myofibroblast transition models.
• Nitric Oxide (NO) Synthesis: Induces endothelial NO synthase (eNOS) activity, promoting vasodilation and reducing vascular inflammation.
• FOXO1 and COX-2 Modulation: Alters transcription factors and inflammatory mediator expression.

Through these mechanisms, Ang-(1-7) opposes many actions of angiotensin II, including oxidative stress, fibrosis, and pro-inflammatory cytokine production (Oliveira et al., 2025). The peptide also enhances insulin sensitivity and promotes lipid metabolism by increasing lipolysis and reducing dyslipidemia. Its cerebroprotective effects involve modulation of neuronal plasticity and reduction in neuroinflammation.

Evidence & Benchmarks

• Ang-(1-7) is produced by enzymatic cleavage of angiotensin I (1-10) or II (1-8) via endo- or carboxypeptidases (Oliveira et al., 2025).
• The heptapeptide sequence of Ang-(1-7) is Asp-Arg-Val-Tyr-Ile-His-Pro (Oliveira et al., 2025).
• Ang-(1-7) activates the Mas receptor, a GPCR, to mediate vasodilation, anti-fibrotic, and anti-inflammatory effects (DOI).
• In NRK-52E rat kidney cell assays, 100 nM Ang-(1-7) inhibits TGF-β-ERK pathway-driven myofibroblast transition; this inhibition is reversed by the Mas antagonist A779 (ApexBio).
• Daily intraperitoneal administration of Ang-(1-7) (0.01–0.06 mg/kg) in BALB/c mice reduces dextran sulfate sodium-induced colitis and lowers phosphorylation of p38, ERK1/2, and Akt (ApexBio).
• Ang-(1-7) is >99.7% pure by HPLC and mass spectrometry, and is soluble in water (≥48.5 mg/mL) and DMSO (≥89.9 mg/mL) but insoluble in ethanol (ApexBio).
• Ang-(1-7) provides cerebroprotection against ischemic stroke and improves learning and memory in preclinical models (Oliveira et al., 2025).
• The peptide enhances glucose uptake, reduces insulin resistance, and modulates lipid metabolism in experimental systems (DOI).

Applications, Limits & Misconceptions

Applications:

• Renal and cardiovascular disease modeling, where anti-fibrotic and anti-inflammatory effects are critical (Angiotensin (1-7): Applied Protocols—this article clarifies the peptide's distinct signaling compared to classical RAS agents).
• Metabolic research, including insulin resistance and dyslipidemia (Angiotensin (1-7): Applied Protocols and Experimental Adv...—here we further document in vivo metabolic benchmarks).
• Oncology, as an anti-proliferative and anti-angiogenic agent (Angiotensin (1-7): Mechanistic Insights and Strategic Hor...—this article updates mechanistic understanding in cancer models).
• Neuroprotection, especially in ischemic stroke and cognitive impairment.

Common Pitfalls or Misconceptions

• Ang-(1-7) does not fully substitute for angiotensin II antagonists in hypertension models; their mechanisms and targets differ.
• Effects of Ang-(1-7) require functional Mas receptor expression; in knockout models, its activity is abolished.
• Ang-(1-7) is not stable in ethanol and should not be dissolved or stored in this solvent.
• Long-term storage of solutions is not recommended; freshly prepared aliquots are preferable for reproducibility.
• Not all anti-inflammatory effects translate across species; validation in the intended model is necessary.

Workflow Integration & Parameters

Ang-(1-7), available as product A1041 (Angiotensin (1-7)), is supplied as a solid with purity >99.7% (HPLC/MS). For cell-based assays, dissolve in sterile water or DMSO (≥48.5–89.9 mg/mL). For renal myofibroblast transition studies, use at 100 nM in NRK-52E cells, with TGF-β co-stimulation and optional A779 antagonist for pathway specificity. For in vivo experiments (e.g., colitis models), administer 0.01–0.06 mg/kg intraperitoneally daily in BALB/c mice. Store lyophilized peptide at -20°C, desiccated; solutions are stable for short-term use only.

Workflow integration is facilitated by high solubility and consistent biological activity. Ang-(1-7) can be co-administered with classical RAS agents to dissect pathway-specific effects. For extended protocols and strategic guidance, see Angiotensin (1-7): Applied Protocols and Angiotensin (1-7): Mechanistic Insights—this article provides updated storage and dosing parameters.

Conclusion & Outlook

Angiotensin (1-7) is a validated Mas receptor agonist with robust anti-fibrotic, anti-inflammatory, metabolic, neuroprotective, and anti-cancer properties, supported by consistent peer-reviewed and experimental evidence. Its high purity, solubility, and defined mechanism of action make it a powerful tool for dissecting RAS biology and related pathologies. Future research may clarify its translational potential in clinical settings, but current evidence positions Ang-(1-7) as a versatile reagent for precision modeling of complex disease networks.